title: Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
abstract: The clinical significance of the immunoexpression of survivin in prostate cancer and its correlation with the biological aggressiveness of prostate cancer remains unclear. Therefore, the present study was undertaken to compare the immunoexpression of survivin in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) as well as to determine whether this immunoexpression could correlate with Gleason score, proliferation activity and prostate specific antigen (PSA) levels. The prostate needle biopsies from 28 patients with elevated serum PSA levels were studied. As a control, 12 needle biopsies of prostate diagnosed as BPH were used. The immunoexpression of survivin was evaluated semiquantitatively, whereas the Ki-67 index was assessed quantitatively. The immunoexpression of survivin and Ki-67 in epithelial cells in the prostate cancer group was significantly increased as compared to BPH cases. In the prostate cancer group there were positive significant correlations between the immunoexpression of survivin and Gleason score as well as Ki‑67 antigen. The correlation between the immunoexpression of survivin and PSA levels was also positive, but it did not reach statistical significance. In conclusion, we can confirm that in prostate cancer the immunoexpression of survivin is augmented as compared to BPH and positively correlated with parameters of tumor aggressiveness.
authors.affiliation: Marian Danilewicz MD, PhD, Department of Pathology, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland, phone/fax +48 42 675 76 33, e-mail: marian.danilewicz@umed.lodz.pl.
authors.forename: Marian
authors.initials: M
authors.lastname: Danilewicz
authors.forename: Olga
authors.initials: O
authors.lastname: Stasikowska-Kanicka
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Wągrowska-Danilewicz
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D001706:Biopsy; D016022:Case-Control Studies; D049109:Cell Proliferation; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis*; D007610:Kallikreins / Q000097:blood; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000737:chemistry* / Q000473:pathology*; D000077022:Survivin; D015854:Up-Regulation
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D019394:Ki-67 Antigen; D000077022:Survivin; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen